{"id":"NCT03277248","sponsor":"TG Therapeutics, Inc.","briefTitle":"Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)","officialTitle":"Phase III: UbLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-08-25","primaryCompletion":"2020-08-04","completion":"2020-11-12","firstPosted":"2017-09-11","resultsPosted":"2021-12-06","lastUpdate":"2021-12-06"},"enrollment":545,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Multiple Sclerosis (RMS)"],"interventions":[{"type":"BIOLOGICAL","name":"Ublituximab","otherNames":["TG-1101"]},{"type":"DRUG","name":"Teriflunomide","otherNames":[]},{"type":"DRUG","name":"Oral Placebo","otherNames":[]},{"type":"DRUG","name":"IV Placebo","otherNames":[]}],"arms":[{"label":"Ublituximab + Oral Placebo","type":"EXPERIMENTAL"},{"label":"Teriflunomide + IV Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.","primaryOutcome":{"measure":"Annualized Relapse Rate (ARR)","timeFrame":"Up to 96 weeks","effectByArm":[{"arm":"Ublituximab + Oral Placebo","deltaMin":0.091,"sd":null},{"arm":"Teriflunomide + IV Placebo","deltaMin":0.178,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0022"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":["39512280","36001711"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":272},"commonTop":["Headache","Nasopharyngitis","Alopecia","Respiratory tract infection","Back pain"]}}